Novocure Ltd (NVCR)

Name: Novocure Ltd (NVCR) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Novocure Ltd (NVCR)

Stock Card

$17.72

$-0.10 (-0.56%)

As on 31-Aug-2026 14:29EDT

Market cap

$2,075 Mln

Revenue (TTM)

$699 Mln

P/E Ratio

P/B Ratio

6.2

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Novocure (NVCR) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 17.39 High: 17.97

52 Week Range

Low: 9.82 High: 21.45

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-6.9
Debt to Equity

0.6
Book Value

$--
EPS

$-1.3
Face value

--
Shares outstanding

116,445,840

10 Years Aggregate

CFO

$-150.74 Mln

EBITDA

$-596.71 Mln

Net Profit

$-794.68 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Novocure (NVCR)	37.0	16.3	4.0	43.7	-6.9	-33.3	8.6
BSE Sensex	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Novocure (NVCR)	-56.6	-79.6	-2.3	-56.6	105.3	151.7
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Novocure (NVCR)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China,... and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. Read more

Executive Chairman

Mr. William F. Doyle
Executive Chairman

Mr. William F. Doyle
Headquarters

Baar
Website

https://www.novocure.com

FAQs for Novocure (NVCR)

What is the current share price of Novocure Ltd (NVCR) Today?

The share price of Novocure Ltd (NVCR) is $17.72 (NASDAQ) as of 31-Aug-2026 14:29 EDT. Novocure Ltd (NVCR) has given a return of -6.86% in the last 3 years.